Joint ePRO Initiative Delivers Ready-to-Use, Patient-Centric Solutions to Speed Trial Times and Enhance Patient Engagement
Medidata (NASDAQ:MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, and ICON plc, (NASDAQ:ICLR) a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced a joint initiative designed to bring new efficiencies to the administration of electronic patient-reported outcomes (ePROs) in clinical trials. By combining Medidata’s best-in-class technology with ICON’s ready-to-use, pre-validated surveys, the new offering provides sponsors with an ePRO solution that reduces costs, saves time and enhances patient engagement.
Medidata Patient Cloud™, an innovative ePRO solution for patient-centric data capture, significantly simplifies trial setup through its configurable interface with the Medidata Clinical Cloud™. ICON brings ready-to-go, pre-validated patient input instruments for fast clinical trial deployment. These productivity enhancements, combined with the Patient Cloud interface available as a mobile app, create an industry-leading solution for capturing patient input in clinical research.
“We are pleased to extend our partnership with Medidata,” commented Dermot Kenny, Executive Vice President, Global Clinical and Data Operations. “Their innovative technology, together with ICON’s market-leading expertise, creates a solution that will help customers reduce study timelines and makes it easier for patients to record their experiences.”
Available on any iOS® device and automatically unified with Medidata’s platform, Patient Cloud provides electronic patient questionnaire and diary functionality in a model that simplifies the setup process, freeing research organizations from the burdens of custom software and proprietary devices. And in simplifying the data capture and patient participation processes, Medidata’s ePRO solution is transforming the clinical trial experience for study participants at a time when capturing the patient voice is becoming increasingly important.
“We’re thrilled to be expanding this partnership and share ICON’s commitment to bringing the voice of the patient to clinical research,” said Glen de Vries, Medidata’s president. “Together, we’re changing how the industry conducts clinical trials by making ePROs applicable to a wider array of studies, reducing the work required to use them and eliminating pain points such as equivalencies and other complicated processes.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.